Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute toxicity, oral route:
In an acute oral toxicity study, no macroscopic findings were recorded at necropsy and no intercurrent deaths occurred during the course of the study.
Furthermore, no clinical signs were recorded throughout the entire observation period. The body weight of the animals was within the range commonly recorded for this strain and age. The median lethal dose of the tested material after single oral administration to rats of both sexes, observed over a period of 14 days, is: LD50 (rat): greater than 2000 mg/kg body weight. Based upon the referred classification criteria (Regulation (EC) No 1272/2008), the substance is not classified with respect to acute oral toxicity.
Acute toxicity, inhalation route:
Data waiving: Since no inhalation is to be expected during the intended use of the material, testing for acute inhalation toxicity is not justified.
Acute toxicity, dermal route:
Data waiving: No systemic toxicity was observed after single oral application of 2000 mg/kg body weight to rats and no clinical effects were observed after three times dermal application of up to 2795 mg/kg body weight in an LLNA assay. Therefore, systemic toxicity of any kind after dermal application is not to be expected and further testing not justified.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- The study was performed between 27 July 2010 and 19 August 2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Study conducted in compliance with agreed protocols, with no or minor deviations from standard test guidelines and/or minor methodological deficiencies, which do not affect the quality of the relevant results. The study report was conclusive, done to a valid guideline and the study was conducted under GLP conditions.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS:
Animals: Rat, RccHan: WIST(SPF)
Rationale: Recognized by international guidelines as a recommended test system.
Breeder: Harlan Laboratories B.V., Kreuzelweg 53, 5961 NM Horst / The Netherlands
Number of Animals per Group: Group 1: 3 females, Group 2: 3 males
Total Number of Animals: 6
Age (when treated): Females: 14 weeks, Males: 12 weeks
Body Weight Range (when treated): Females: 200.8 g – 221.6 g, Males: 344.5 g – 360.9 g
Identification: Unique cage number and corresponding color-coded spots on the tail. The animals were marked at acclimatization start.
Randomization: Selected by hand at time of delivery. No computer generated randomization program.
Acclimatization: 7 (Group 1) or 9 (Group 2) days under laboratory conditions, after health examination. Only animals without any visible signs of illness were used for the study.
ENVIRONMENTAL CONDITIONS:
Conditions: Standard Laboratory Conditions. Air-conditioned with 10-15 air changes per hour, and continuously monitored environment with a room temperature of 22 ± 3 °C and a relative humidity between 30-70%, automatically controlled light cycle of 12 hours light and 12 hours dark and music played during the daytime light period.
Accommodation: In groups of three in Makrolon type-4 cages with wire mesh tops and standard softwood bedding (‘Lignocel’ J. Rettenmaier&Söhne GmbH&CoKG, 73494 Rosenberg / Germany, imported by Provimi Kliba AG, 4303 Kaiseraugst / Switzerland), including paper enrichment, batch no. -67 (Envirodri from Lillico, Biotechnology, Surrey / UK).
Diet: Pelleted Teklad Rat-Mouse Diet 2914C, batch no. 20/10 (provided by Provimi Kliba AG, 4303 Kaiseraugst / Switzerland) ad libitum (except for the overnight fasting period prior to oral administration and approximately 3-4 hours post dose). Results of analyses for contaminants were archived at Harlan Laboratories Ltd.
Water: Community tap water from Füllinsdorf ad libitum. Results of bacteriological, chemical and contaminant analyses are archived at Harlan Laboratories Ltd. - Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Remarks:
- The vehicle was chosen after a non-GLP solubility trial which was performed before the study initiation date. According to the Sponsor’s specification, the test item was not stable in water. Therefore, polyethylenglycol 300 (PEG 300) was identified as sui
- Details on oral exposure:
- PREPARATION OF DOSE FORMULATIONS:
Dose levels are in terms of the test item as supplied by the Sponsor. The dose formulations were prepared shortly before each dosing occasion using a magnetic stirrer and a spatula as homogenizers. The test item was weighed into a tared glass beaker on a suitable precision balance and the vehicle was added (weight:volume). Homogeneity of the test item in the vehicle was maintained during administration using a magnetic stirrer.
TEST ITEM ADMINISTRATION:
Dosing started in three female animals at a dosage level of 2000 mg/kg. Since no mortality occurred, a confirming dose group consisting of three male animals was administered at the same dose level. The animals received a single dose of the test item by oral gavage administration at 2000 mg/kg
body weight after being fasted for approximately 18 to 19 hours (access to water was permitted). Food was provided again approximately 3 hours after dosing. The dosing volume was 10 mL/kg body weight. Rationale: Oral administration was considered to be an appropriate application method as it is a possible route of human exposure during manufacture, handling and use of the test item. - Doses:
- 2000 mg/kg body weight
- No. of animals per sex per dose:
- 3 females
3 males - Control animals:
- no
- Details on study design:
- PURPOSE:
The purpose of this study was to assess the acute toxicity of Sa 57 when administered by single oral gavage to rats, followed by an observation period of 14 days. This study provides information for both hazard assessment and hazard classification purposes.
OBSERVATIONS:
Viability / Mortality: Daily during acclimatization. Once before treatment and within the first 30 minutes and at approximately 1, 2, 3 and 5 hours after treatment on test day 1 (in common with the clinical signs). Twice daily during days 2 – 15.
Clinical Signs: Daily during acclimatization and treatment. Additionally, within the first 30 minutes and at approximately 1, 2, 3 and 5 hours after
administration on test day 1.
Body Weights: On test days 1 (prior to administration), 8 and 15.
PATHOLOGY:
Necropsy: All animals were killed at the end of the observation period by carbon dioxide asphyxiation and discarded after macroscopic examinations were performed. An external examination and opening of the abdominal and thoracic cavities for examinations of major organs was performed. The
appearance of any macroscopic abnormalities was recorded. No organs or tissues were retained.
DATA COMPILATION:
Viability/mortality was recorded on data sheets. Body weights were recorded on-line with the ToxControl Computer System. Clinical signs, mortality data and macroscopic findings were compiled into the ToxControl Computer System during recording. The ToxControl Computer System has been licensed for Harlan Laboratories Ltd. and validated with respect to data collection, storage and retrievability. - Statistics:
- No statistical analysis was performed.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No intercurrent deaths occurred during the course of the study.
- Clinical signs:
- other: No clinical signs were recorded throughout the entire observation period.
- Gross pathology:
- No macroscopic findings were recorded at necropsy.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The median lethal dose of Sa 57 after single oral administration to rats of both sexes, observed over a period of 14 days, is:
LD50 (rat): greater than 2000 mg/kg body weight - Executive summary:
Two groups, one consisting of three female and one consisting of three male RccHan:WIST (SPF) rats, were treated with Sa 57 by single oral gavage administration at a dosage of 2000 mg/kg body weight. The test item was formulated in PEG 300 at a concentration of 0.2 g/mL and administered at a dosing volume of 10 mL/kg.
The animals were examined daily during the acclimatization period and mortality, viability and clinical signs were recorded. All animals were examined for clinical signs before treatment, within the first 30 minutes and approximately 1, 2, 3 and 5 hours after treatment on day 1 and once daily during test days 2-15. Mortality/viability was recorded before treatment, within the first 30 minutes and approximately 1, 2, 3 and 5 hours after administration on test day 1 (with the clinical signs) and twice daily during days 2-15. Body weights were recorded on day 1 (prior to administration) and on days 8 and 15. All animals were necropsied and examined macroscopically.
No intercurrent deaths occurred during the course of the study.
No clinical signs were recorded throughout the entire observation period.
The body weight of the animals was within the range commonly recorded for this strain and age.
No macroscopic findings were recorded at necropsy.
The median lethal dose of Sa 57 after single oral administration to rats of both sexes, observed over a period of 14 days, is: LD50 (rat): greater than 2000 mg/kg body weight
Based upon the referred classification criteria (Regulation (EC) No 1272/2008), Sa 57 is not classified with respect to acute oral toxicity.
Reference
Due to the nature of the data all tables have been attached:
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- > 2 000 mg/kg bw
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
Acute Toxicity: oral
Based on the acute oral LD50 in rats (>2000 mg/kg) the substance does not need to be classified for acute toxicity according to EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.